ASCIONE, LILIANA
ASCIONE, LILIANA
Universita' degli Studi di MILANO
Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy
2025 D. Izzo, L. Ascione, L. Guidi, R.M. Marsicano, C. Koukoutzeli, D. Trapani, G. Curigliano
Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer
2024 C. Koukoutzeli, D. Trapani, L. Ascione, E. Kotteas, A. Marra, C. Criscitiello, G. Curigliano
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience
2024 E. Crimini, G. Tini, P. Tarantino, L. Ascione, M. Repetto, P. Beria, A. Ranghiero, A. Marra, C. Belli, C. Criscitiello, A. Esposito, E. Guerini Rocco, M.C.P. Barberis, L. Mazzarella, G. Curigliano
Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives
2024 L. Ascione, G. Castellano, G. Curigliano, P. Zagami
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
2024 L. Mazzarella, F. Giugliano, E. Nicolo, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. D'Amico, P.T. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P.P.M. Berton Giachetti, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit
2024 A. Esposito, E. Crimini, C. Criscitiello, C. Belli, R. Scafetta, R. Scalia, G. Castellano, E. Giordano, J. Katrini, L. Ascione, L. Boscolo Bielo, M. Repetto, A. Marra, D. Trapani, G.M. Varano, D. Maiettini, P. Della Vigna, F. Orsi, E. Guerini Rocco, N. Fusco, G. Curigliano
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers
2024 C. Belli, L. Boscolo Bielo, M. Repetto, E. Crimini, R. Scalia, A. Diana, J. Orefice, L. Ascione, G. Pellizzari, N. Fusco, M. Barberis, B. Daniele, E. Guerini-Rocco, G. Curigliano
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology
2024 L. Boscolo Bielo, C. Belli, E. Crimini, M. Repetto, L. Ascione, G. Pellizzari, C. Santoro, V. Fuorivia, M. Barberis, N. Fusco, E.G. Rocco, G. Curigliano
Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates
2024 L. Ascione, L. Guidi, A. Prakash, D. Trapani, P. Lorusso, E. Lou, G. Curigliano
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
2023 L. Ascione, E. Crimini, D. Trapani, A. Marra, C. Criscitiello, G. Curigliano
Screening Programs for Breast Cancer: Toward Individualized, Risk-Adapted Strategies of Early Detection
2023 D. Trapani, J. Sandoval, P.T. Aliaga, L. Ascione, P.P. Maria Berton Giachetti, G. Curigliano, O. Ginsburg
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience
2023 M. Repetto, E. Crimini, L. Boscolo Bielo, E. Guerini-Rocco, L. Ascione, A. Bonfanti, C. Zanzottera, L. Mazzarella, A. Ranghiero, C. Belli, C. Criscitiello, A. Esposito, M.C.P. Barberis, G. Curigliano
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases
2023 P. Trillo, J. Sandoval, D. Trapani, E. Nicolò, P. Zagami, F. Giugliano, P. Tarantino, G. Vivanet, L. Ascione, A. Friedlaender, A. Esposito, C. Criscitiello, G. Curigliano
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study
2023 S. Morganti, A. Marra, S. Gandini, L. Ascione, M. Ivanova, K. Venetis, E. Sajjadi, P. Zagami, F. Giugliano, B. Taurelli Salimbeni, P.P.M. Berton Giachetti, C. Corti, E. De Camilli, G. Curigliano, N. Fusco, C. Criscitiello
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data
2023 M. Repetto, E. Crimini, C. Belli, L. Boscolo Bielo, L. Ascione, F. Meric-Bernstam, A. Drilon, G. Curigliano
PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
2022 L. Ascione, P. Zagami, E. Nicolò, E. Crimini, G. Curigliano, C. Criscitiello
Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls
2022 S. Morganti, M. Ivanova, E. Ferraro, L. Ascione, G. Vivanet, G. Bonizzi, G. Curigliano, N. Fusco, C. Criscitiello
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
2022 E. Nicolò, F. Giugliano, L. Ascione, P. Tarantino, C. Corti, S.M. Tolaney, M. Cristofanilli, G. Curigliano
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer
2022 S. Morganti, A. Marra, K. Venetis, E. Sajjadi, L. Ascione, C. Corti, P. Zagami, M. Ivanova, L. Zattoni, G. Curigliano, N. Fusco, C. Criscitiello
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046
2022 M. Repetto, E. Crimini, L. Ascione, L. Boscolo Bielo, C. Belli, G. Curigliano